Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-lasting residual efficacy of a new indoor residual spraying product, VECTRON™ T500 (broflanilide), against pyrethroid-resistant malaria vectors and its acceptance in a community trial in Burkina Faso.
Hien AS, Bayili K, Maiga S, Oumbouke W, Birba J, Soma DD, Ouattara AY, Karama DO, Coleman M, Snetselaar J, Small G, Niimi S, Ayumi K, Kompaoré S, Tsuchiya K, Dabiré RK, Diabaté A. Hien AS, et al. Among authors: maiga s. Parasit Vectors. 2024 Nov 23;17(1):484. doi: 10.1186/s13071-024-06577-y. Parasit Vectors. 2024. PMID: 39580476 Free PMC article. Clinical Trial.
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.
Durand R, Bellanger C, Descamps G, Dousset C, Maïga S, Derrien J, Thirouard L, Bouard L, Asnagli H, Beer P, Parker A, Gomez-Bougie P, Devilder MC, Moreau P, Touzeau C, Moreau-Aubry A, Chiron D, Pellat-Deceunynck C. Durand R, et al. Among authors: maiga s. Hemasphere. 2024 Oct 8;8(10):e70016. doi: 10.1002/hem3.70016. eCollection 2024 Oct. Hemasphere. 2024. PMID: 39380841 Free PMC article.
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.
Carretero-Iglesia L, Hall OJ, Berret J, Pais D, Estoppey C, Chimen M, Monney T, Loyau J, Dreyfus C, Macoin J, Perez C, Menon V, Gruber I, Laurendon A, Caro LN, Gudi GS, Matsuura T, van der Graaf PH, Blein S, Mbow ML, Croasdale-Wood R, Srivastava A, Dyson MR, Matthes T, Kaya Z, Edwards CM, Edwards JR, Maiga S, Pellat-Deceunynck C, Touzeau C, Moreau P, Konto C, Drake A, Zhukovsky EA, Perro M, Pihlgren M. Carretero-Iglesia L, et al. Among authors: maiga s. Nat Cancer. 2024 Oct;5(10):1494-1514. doi: 10.1038/s43018-024-00821-1. Epub 2024 Sep 11. Nat Cancer. 2024. PMID: 39261676 Free PMC article.
Azithromycin to Reduce Mortality - An Adaptive Cluster-Randomized Trial.
O'Brien KS, Arzika AM, Amza A, Maliki R, Aichatou B, Bello IM, Beidi D, Galo N, Harouna N, Karamba AM, Mahamadou S, Abarchi M, Ibrahim A, Lebas E, Peterson B, Liu Z, Le V, Colby E, Doan T, Keenan JD, Oldenburg CE, Porco TC, Arnold BF, Lietman TM; AVENIR study group. O'Brien KS, et al. N Engl J Med. 2024 Aug 22;391(8):699-709. doi: 10.1056/NEJMoa2312093. N Engl J Med. 2024. PMID: 39167806 Clinical Trial.
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Durand R, Descamps G, Bellanger C, Dousset C, Maïga S, Alberge JB, Derrien J, Cruard J, Minvielle S, Lilli NL, Godon C, Le Bris Y, Tessoulin B, Amiot M, Gomez-Bougie P, Touzeau C, Moreau P, Chiron D, Moreau-Aubry A, Pellat-Deceunynck C. Durand R, et al. Among authors: maiga s. Blood. 2024 Mar 28;143(13):1242-1258. doi: 10.1182/blood.2023021581. Blood. 2024. PMID: 38096363
74 results